BIA
MRNA icon

Biondo Investment Advisors’s Moderna MRNA Stock Holding History

Biondo Investment Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,105
Closed -$2.8M – 87
2023
Q3 		$2.8M Buy
27,105
+1,927
+8% +$215K 0.53% 43
2023
Q2 		$3.06M Buy
25,178
+478
+2% +$63.8K 0.57% 40
2023
Q1 		$3.79M Buy
24,700
+515
+2% +$85K 0.77% 40
2022
Q4 		$4.34M Sell
24,185
-134
-0.6% -$21.9K 0.97% 37
2022
Q3 		$2.88M Buy
24,319
+777
+3% +$118K 0.66% 41
2022
Q2 		$3.36M Buy
23,542
+330
+1% +$47.2K 0.74% 41
2022
Q1 		$4M Sell
23,212
-1,190
-5% -$200K 0.7% 41
2021
Q4 		$6.2M Buy
24,402
+47
+0.2% +$13.7K 1.03% 36
2021
Q3 		$9.37M Buy
24,355
+60
+0.2% +$22.1K 1.61% 20
2021
Q2 		$5.71M Buy
+24,295
New +$4.34M 0.98% 41

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Biondo Investment Advisors's MRNA Position: Q4 2023 in Review

Biondo Investment Advisors sold out of Moderna (MRNA) in Q4 2023, closing a stake of 27,105 shares — an estimated $2.8M sold.

Biondo Investment Advisors first reported a position in MRNA in Q2 2021 and held it in 10 quarters. The position peaked at $9.37M in Q3 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Biondo Investment Advisors reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Biondo Investment Advisors sold 27,105 Moderna shares in Q4 2023, an estimated $2.8M.
  • Biondo Investment Advisors first reported a position in Moderna in Q2 2021 and held it in 10 quarters.
  • Biondo Investment Advisors's Moderna position peaked at $9.37M in Q3 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Biondo Investment Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.